PepGen (PEPG) Projected to Post Earnings on Wednesday

PepGen (NASDAQ:PEPG - Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

PepGen (NASDAQ:PEPG - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.13. On average, analysts expect PepGen to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PepGen Stock Up 29.6 %

Shares of PEPG stock traded up $0.72 during trading hours on Friday, reaching $3.15. The company's stock had a trading volume of 8,938,895 shares, compared to its average volume of 4,157,341. PepGen has a fifty-two week low of $1.16 and a fifty-two week high of $19.30. The company has a market capitalization of $102.68 million, a price-to-earnings ratio of -1.06 and a beta of 1.53. The firm's 50 day simple moving average is $2.37 and its 200-day simple moving average is $5.69.

Analyst Ratings Changes

Several equities research analysts recently weighed in on PEPG shares. Bank of America downgraded PepGen from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a report on Monday, December 16th. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of PepGen in a report on Monday, February 24th. Finally, Wedbush cut their price objective on PepGen from $19.00 to $12.00 and set an "outperform" rating on the stock in a report on Friday, November 8th.

Remove Ads

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.